Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › SUNPHARMA

SUNPHARMA

Sun Pharmaceutical Industries Limited
Large-capPharma ↗

What the six lenses say about SUNPHARMA — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1938.7
2026-07-10
VWAP · 1Y anchor
₹1721
+12.7% from VWAP
P/E · TTM
40.5×
TTM EPS ₹47.9
52-week range
100%
position low→high
RSI(14)
71
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How SUNPHARMA’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
7.0
avg conviction decile
Leadership
1/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Large-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+12.7%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+9.9%
Price vs 50-EMA+5.7%
RSI(14)71
RS vs Nifty 500 · 3M+13.9%
RS vs sector · 3M+1.4%
52-week range100%
Volume vs 30d avg0.60×
Volume vs 60d avg0.42×
ATR(14) · volatility38.4
Bollinger width · vol contraction0.078
FundamentalD868›

The actual numbers

Return on equity (ROE)16.0%
Return on capital (ROCE)20.5%
Operating margin26.4%
Net margin19.7%
Revenue growth · YoY+11.2%
EPS growth · YoY+5.0%
Debt / equity0.06×

Full 8-quarter history in the financials table below.

ValuationD212›

The actual numbers

P/E (TTM)40.5×
TTM EPS₹47.9
52-week range100%
CatalystD648›

The actual numbers

Earnings & momentum50
Capital actions17
Governance124

Every filing in the corporate-announcements panel below.

FlowD450›

The actual numbers

Promoter holding54.5%
Delivery · 30d avg61.8%
Up/down-day asymmetry-3.2pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Large-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D4 ) ÷ 2 = 7.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
95
Conviction score 95/100 · avg-decile strength 7.0/10
Conviction score95/100›
TechnicalD10›
FundamentalD8›
ValuationD2›
CatalystD6›
FlowD4›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+2.3pp
+4.5pp
+5.3pp
+17.5pp
+18.8pp
+22.1pp
Nifty 500
Broad-market baseline
+1.9pp
+4.4pp
+4.7pp
+13.9pp
+13.7pp
+18.3pp
Sector
Own-sector index
—
—
+2.3pp
+1.4pp
-0.7pp
+0.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

SUNPHARMA daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1938.70+50.50

Relative strength

RS vs baseline · rebased to 100

SUNPHARMA ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
120.73+2.26

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)12,65313,29113,67512,95913,85114,47815,52114,612
↳ change QoQ—+5.0%+2.9%-5.2%+6.9%+4.5%+7.2%-5.9%
EBITDA (₹cr)4,1404,2934,1583,7164,3024,5274,9483,954
EBITDA margin32.7%32.3%30.4%28.7%31.1%31.3%31.9%27.1%
PAT (₹cr)2,8613,0372,9132,1542,2933,1253,3812,710
↳ change QoQ—+6.2%-4.1%-26.1%+6.5%+36.3%+8.2%-19.8%
Net margin22.6%22.9%21.3%16.6%16.6%21.6%21.8%18.6%
EPS (₹)11.8012.7012.108.969.5013.0014.0411.31
D/E————————
YoY growth · Mar '26Revenue +12.8% YoYPAT +25.8% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 14 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 25 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 22 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 18 May '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 May '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds SUNPHARMA

Mutual funds holding SUNPHARMA (10)

FundWeightAUM ₹crGrade
ICICI Prudential Large Cap Gr2.52%76,297
ICICI Prudential Large Cap Instl I Gr2.52%76,297
Kotak Flexicap Reg Gr1.07%55,850
SBI Large Cap Reg Gr1.86%55,064
Nippon India Multi Cap Bns0.91%54,585
Nippon India Multi Cap Dir Bns0.91%54,585
Nippon India Multi Cap Gr0.91%54,585
Nippon India Large Cap Gr2.81%53,227
Nippon India Large Cap Bns2.81%53,227
Nippon India Large Cap Instl Bns2.81%53,227

ETFs holding SUNPHARMA (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF21.30%
Aditya BSL Nifty Healthcare ETF18.37%
DSP Nifty Healthcare ETF18.36%
Axis NIFTY Healthcare ETF18.36%
ICICI Pru Nifty Healthcare ETF18.13%
Motilal Oswal BSE Healthcare ETF13.20%
Mirae Asset Nifty 500 Healthcare ETF9.22%
Mirae Asset Nifty Top 20 Eq Weight ETF5.07%
Nippon India Nifty India Manufactrng ETF4.75%
UTI BSE Sensex ETF2.21%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma